(Q45289238)

11 December 2017

title

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects (English)

1 reference

11 December 2017

main subject

piperacillin/tazobactam

1 reference

Gurudatt Chandorkar

1

1 reference

11 December 2017

Jennifer A Huntington

2

1 reference

11 December 2017

Mark H Gotfried

3

1 reference

11 December 2017

Keith A Rodvold

4

1 reference

11 December 2017

Obiamiwe Umeh

5

1 reference

11 December 2017

language of work or name

English

0 references

publication date

6 July 2012

1 reference

Journal of Antimicrobial Chemotherapy

11 December 2017

published in

1 reference

11 December 2017

volume

67

1 reference

11 December 2017

issue

10

1 reference

11 December 2017

page(s)

2463-2469

1 reference

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Update on the treatment of Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Epidemiology of healthcare-associated pneumonia (HCAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Predicting the efficacy of antimicrobial agents in respiratory infections--is tissue concentration a valid measure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

Inhibition of the renal excretion of tazobactam by piperacillin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS246

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS246

1 reference

11 December 2017

1 reference